A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer
Clinical trial NCT07491822 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07491822
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-25
- Primary completion
- 2027-09-15
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.